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Pachyonychia congenita type 2 is an inherited ecto-
dermal dysplasia characterized by hypertrophic nail
dystrophy and multiple pilosebaceous cysts. Focal
nonepidermolytic palmoplantar keratoderma, natal
teeth, and pili torti may also be present. Epithelial
tissues affected in pachyonychia congenita type 2
express the keratin pair K6b/K17. Here, we report
three novel heterozygous mutations in the K17 gene
(KRT17A) in patients presenting with pachyonychia
congenita type 2. These mutations, R94±98del (dele-
tion of the peptide sequence RLASY) and missense
mutations R94P and L95Q, are all within the 1A
domain hotspot for pathogenic keratin mutations.
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P
achyonychia congenita (PC) includes a range of
ectodermal dysplasias where hypertrophic nail dystrophy
is the main clinical feature (Gorlin et al, 1976). PC is
normally inherited in an autosomal dominant manner
and is subdivided into two main types: PC-1 (Jadassohn
and Lewandowsky, 1906) and PC-2 (Jackson and Lawler, 1951). In
the PC-2 variant (OMIM number 167210), characteristic multiple
pilosebaceous cysts develop during puberty. Patients may also have
natal teeth, pili torti, mild focal nonepidermolytic palmoplantar
keratoderma, or oral leukokeratosis; however, these features show
variable expression (Munro et al, 1994).
Keratins are structural proteins found in all epithelial cells (Lane,
1993). They are divided into type I (K9±20) and type II (K1±8)
keratins, and are normally expressed in pairs consisting of one of
each type, in a tissue- and differentiation-speci®c manner. Speci®c
pairs of type I and type II keratins form heteropolymeric 10 nm
intermediate ®laments that serve to protect epithelial cells from
physical damage (McLean and Lane, 1995). K17 is expressed in the
nail bed, sebaceous glands, hair follicles, and other epidermal
appendages (Troyanovsky et al, 1989; McGowan and Coulombe,
2000). Several keratins are thought not to possess a unique partner
and, until recently, K17 was thought to fall in this category. It has
now been shown by in situ hybridization, however, that the K6b
isoform of K6 colocalizes with K17 in epidermal adnexae (Smith
et al, 1998).
Pathogenic mutations in keratin genes are now known to
underlie a range of human epithelial fragility disorders with the
majority of mutations occurring in the helix boundary motifs,
highly conserved regions at either end of the rod domain (Fuchs
and Cleveland, 1997; Irvine and McLean, 1999). Four keratin
genes are associated with PC. Mutations in type I K16 or type II
K6a cause PC-1 (Bowden et al, 1995; McLean et al, 1995) and
mutations in type I K17 or type II K6b lead to PC-2 (McLean et al,
1995; Smith et al, 1998). The discovery of a mutation in K6b in a
family with PC-2 provided evidence that K6b and K17 are a bone
®de keratin pair (Smith et al, 1998). Mutations in K17 also cause
steatocystoma multiplex, a variant of PC-2 characterized by
multiple pilosebaceous cysts but with very little or no nail
involvement (Covello et al, 1998). In some cases, the same
mutation in K17 has been reported to give rise to both PC-2 and
steatocystoma multiplex demonstrating phenotypic variation
regardless of the speci®c mutation (Covello et al, 1998).
Here, we report three novel mutations in the K17 gene in
patients presenting with the PC-2 phenotype.
MATERIALS AND METHODS
Mutation detection and con®rmation Genomic DNA was extracted
from whole blood by standard procedures. A 978 bp fragment spanning
exon 1 of the K17 gene was ampli®ed from genomic DNA using a
primer pair speci®c to K17 (K17P8 and K17P10) in order to avoid
pseudogene contamination as previously described (McLean et al, 1995),
except that 1 mM MgCl2 and 4% dimethylsulfoxide (DMSO) were used,
greatly improving this reaction. Polymerase chain reaction (PCR)
products were puri®ed using QIA quick PCR puri®cation kit (Qiagen,
Crawley, England) and directly sequenced on an ABI 377 Genetic
Analyzer (ABI, Foster City, CA) using forward primer K17P3 5¢ TAT
GGC AGC AGC TTT GGG and reverse primer K17P4 5¢ GGT ACC
AGT CAC GGA TCT TCA 3¢. Each mutation was excluded from 50
normal, unrelated individuals by restriction enzyme analysis or
conformation sensitive gel electrophoresis (CSGE; Ganguly et al, 1993).
For mutation R94±98del, the deletion was con®rmed by cloning the
978 bp fragment (K17P8±K17P10) into pCR2.1 vector (InVitrogen,
Groningen, The Netherlands). This mutation was excluded from a
normal population by CSGE. Genomic DNA was ampli®ed as above
and the PCR products were analyzed on 8% CSGE gels without further
puri®cation. Gels were stained with ethidium bromide (0.05 mg per ml)
for 15 min and fragments were visualized under ultraviolet light.
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Mutation R94P does not alter any known restriction enzyme site.
Using a primer with a mismatch base, a new Sma I site was created in
combination with the mutation. Nested PCR reactions were performed
to avoid pseudogene contamination. Genomic DNA was ®rst ampli®ed
as above and a second round of PCR was performed to amplify a 282
bp fragment with primers K17P12 5¢ CAC CTC CTC CAG CTC
CAT CAA G 3¢ and K17PGG 5¢ ACC TTG TCC AGG TAG GAG
GCC CGG 3¢ (mismatch underlined). PCR was performed in 1 3 PCR
buffer (Promega, Madison, WI) containing 1 mM MgCl2 and 4%
DMSO. PCR conditions were 94°C 5 min 3 1, followed by 30 cycles
of 94°C 30 s, 55°C 45 s, 72°C 1 min, and 72°C 5 min 3 1. Diluted
PCR products were digested overnight at 27°C with 5 U Sma I
(Promega) and analyzed on 3.5% agarose gels.
Mutation L95Q creates a new Stu I site, which was used to exclude
the mutation from normal individuals. Using primers K17P8 and
K17P10 (above), genomic DNA was ampli®ed, followed by a second
round of PCR to amplify a 338 bp fragment using primers K17P12 and
K17P4 (above). Reaction conditions were as for K17P12±K17PGG
(above). PCR products were diluted and digested overnight at 37°C
with 5 U Stu I. Digests were analyzed on 3% agarose gels.
DNA ®ngerprinting For paternity testing in sporadic cases, the
Second Generation Multiplex (SGM) set of seven short tandem repeat
markers was used (Sparkes et al, 1996). Microsatellite markers were
labeled with ¯uorescent dyes and analyzed on an ABI 377 Genetic
Analyzer using ABI Genescan and Genotyper software (ABI).
RESULTS
Clinical ®ndings Family 1 were of Italian Caucasian ethnicity
and showed typical autosomal dominant inheritance of PC-2
through two generations. The proband is the second daughter of
unrelated parents. Her mother was affected with PC-2 as was her
older sister, who died at 4 mo of age from bronchopneumonia,
presumably unrelated to the pachyonychia phenotype. The clinical
®ndings of this family have been described previously (Clementi
et al, 1986).
The proband in family 2 was a female Australian Caucasian
presenting with typical features of PC-2 as a sporadic case.
Interestingly, the proband's paternal grandfather and paternal uncle
had been diagnosed with epidermolysis bullosa simplex, although
the patient's father showed no signs of either the latter disorder or
pachyonychia.
Family 3 was also a sporadic French Caucasian case who was
born with three natal teeth, indicative of PC-2. Now at 3 y of age,
she has pachyonychia of all ®ngernails and toenails, and oral
leukokeratosis with two small white patches on the tongue. She has
no signs of palmar or plantar hyperkeratosis.
Identi®cation and con®rmation of novel mutations in
K17 Direct sequencing of PCR products revealed mutations in
exon 1 of the K17 gene in all three patients. In the proband of
family 1, overlapping sequence traces were found, indicative of a
deletion mutation (not shown). Cloning the K17 PCR fragment
into pCR2.1 vector revealed two species of clones: one with the
normal sequence and a second with a 15 bp deletion mutation,
designated 279del15 (Fig 1a, b). This defect removes ®ve amino
acids (RLASY) from the helix initiation motif of the K17 protein
(designated R94±98del). CSGE was used to exclude the mutation
from 50 normal, unrelated individuals. In the proband, the smaller
mutant allele could be separated from the normal allele and two
bands were observed due to heteroduplex formation (Fig 2a). In
contrast, all 50 control samples showed a single homoduplex band.
Heterozygous transversion mutation 281G > C was found in
family 2 resulting in the predicted amino acid change R94P
(Fig 1c). This mutation does not create or destroy any known
restriction enzyme site so a primer with a mismatch base was
designed that creates a new Sma I site in combination with the
mutation. Analysis of PCR products digested with Sma I con®rmed
the mutation in the affected individual and excluded it from the
unaffected parents and 50 normal, unrelated individuals (Fig 2b).
In the third family, the affected individual was heterozygous for
the transition 284T > A leading to the predicted amino acid
change L95Q (Fig 1d). This mutation creates a new Stu I site that
was used to exclude the mutation from the unaffected parents and
50 normal, unrelated individuals (Fig 2c).
DISCUSSION
In the three PC cases studied, one familial and two sporadic, novel
mutations were identi®ed in the helix initiation motif of K17. The
279del15 mutation in family 1 is the ®rst report of a deletion in K17
and leads to removal of the amino acid sequence RLASY (R94±
98del) from the highly conserved 1A domain of the K17 protein
(deletion of 1A domain residues 10±14). Missense mutations, R94P
and L95Q, were detected in affected individuals of the other two
Figure 1. Keratin 17 mutation analysis. (a) Normal K17 sequence in
exon 1, corresponding to codons 91±100, base numbers 271±300,
inclusive. The 15 bases deleted in family 1 are boxed (b, below). (b)
Sequence of a cloned mutant allele in pCR2.1 vector. The same region
shown in (a), derived from the proband in family 1, showing the
deletion 279del15 that removes ®ve amino acids (R94±98del). (c) The
equivalent sequence shown in (a) from the affected individual in family 2
showing heterozygous missense mutation 281G > C (arrow) that predicts
the amino acid substitution R94P. (d) The equivalent sequence shown in
(a) derived from the affected individual in family 3 showing missense
mutation 284T > A (arrow) leading to amino acid change L95Q.
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cases, again in the 1A domain (1A residues R10P and L11P).
Previously, all reported mutations in PC-2, like those detected in
families 2 and 3 here, have been heterozygous missense mutations in
K17 (McLean et al, 1995; Smith et al, 1997; Covello et al, 1998;
Fujimoto et al, 1998; Celebi et al, 1999). Interestingly, the 279del15
mutation produces a similar clinical phenotype to that seen with
missense mutations in this region (Clementi et al, 1986). This is in
contrast to a family reported with a 24 bp deletion in the 2B domain
of K16, who presented with a very mild focal nonepidermolytic
palmoplantar keratoderma phenotype (Smith et al, 2000). Larger
deletions that completely remove a keratin helix boundary motif
might be expected to have a milder dominant-negative effect due to
loss of these critical molecular overlap regions (Steinert et al, 1993).
Although this does not appear to be the case in family 1 here, it is
possible that a larger deletion in this vicinity might result in a milder
disease. Such unusual mutations are invaluable in de®ning the
functionally critical regions of the keratin rod domain, thus
emphasizing the need for continued mutation analysis.
Including this study, all reported K17 mutations are in the helix
initiation motif at the start of the alpha helical rod domain (Irvine and
McLean, 1999). Similar missense or small in-frame insertion/
deletion mutations in the helix termination motif at the opposite end
of the rod domain are also predicted to produce PC-2, although
none has been reported to date. K6b and K17 are now known to be
coexpressed and with one report of a mutation in K6b it is likely that
some PC-2 families where no mutation in K17 has been identi®ed
may have pathogenic mutations in K6b (Smith et al, 1998).
In conclusion, we report three novel mutations in K17 and show
that in-frame deletions in this gene, in addition to missense
mutations, can cause PC-2.
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Figure 2. Keratin 17 mutation conformation. (a) Con®rmation of
mutation R94±98del by CSGE. Lane 1: PCR product derived from the
patient shows a heteroduplex band representing the normal and mutant
alleles; lanes 2±6 are homoduplex bands from unrelated unaffected
individuals. (b) Con®rmation of mutation R94P by Sma I digestion.
Lane 1: digested PCR product from the affected individual gives an
additional band due to introduction of an Sma I site in one primer that
depends on the mutation. Lanes 2±5 are digested PCR products from
normal unrelated controls. (c) Con®rmation of mutation L95Q by Stu I
digestion. Lane 1: digestion of PCR product from the affected individual
shows an additional band due a new Stu I site created by the mutation.
Lanes 2±5 show digested PCR products from normal unrelated controls.
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